$CCEL
CRYO CELL INTERNATIONAL INC

2018 Q4 Form 10-Q Financial Statement

#000119312518299303 Filed on October 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $8.594M $7.871M $6.896M
YoY Change 32.82% 14.14% 8.91%
Cost Of Revenue $2.675M $2.486M $1.977M
YoY Change 63.1% 25.72% 27.48%
Gross Profit $5.919M $5.385M $4.918M
YoY Change 22.29% 9.49% 2.88%
Gross Profit Margin 68.87% 68.41% 71.32%
Selling, General & Admin $4.120M $4.391M $3.433M
YoY Change 16.37% 27.91% -12.24%
% of Gross Profit 69.6% 81.53% 69.79%
Research & Development $26.92K $22.23K $226.00
YoY Change 34.6% 9738.05% -98.36%
% of Gross Profit 0.45% 0.41% 0.0%
Depreciation & Amortization $103.1K $94.28K $60.00K
YoY Change 71.75% 57.13% -14.29%
% of Gross Profit 1.74% 1.75% 1.22%
Operating Expenses $4.202M $4.413M $3.433M
YoY Change 17.04% 28.55% -12.55%
Operating Profit $1.717M $920.1K $1.452M
YoY Change 37.36% -36.64% -236.74%
Interest Expense -$551.5K $410.4K $314.9K
YoY Change 49.04% 30.32% 57.89%
% of Operating Profit -32.12% 44.6% 21.68%
Other Income/Expense, Net -$39.24K -$372.1K -$309.7K
YoY Change 96.2% 20.15% -87.52%
Pretax Income $1.542M $548.1K $1.143M
YoY Change 79.26% -52.03% -132.25%
Income Tax $557.7K $303.1K $490.6K
% Of Pretax Income 36.18% 55.3% 42.93%
Net Earnings $890.8K $245.0K $652.0K
YoY Change 30.99% -62.43% -124.66%
Net Earnings / Revenue 10.37% 3.11% 9.46%
Basic Earnings Per Share $0.03 $0.09
Diluted Earnings Per Share $114.2K $0.03 $0.08
COMMON SHARES
Basic Shares Outstanding 7.801M shares 7.695M 7.100M shares
Diluted Shares Outstanding 8.376M 7.795M shares

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.916M $7.990M $5.190M
YoY Change 2.91% 53.94% 95.11%
Cash & Equivalents $6.040M $7.040M $4.667M
Short-Term Investments $875.7K $949.8K $520.0K
Other Short-Term Assets $254.5K $209.2K $183.1K
YoY Change 23.45% 14.24% 290.96%
Inventory $1.261M $16.17M $335.8K
Prepaid Expenses $461.8K $597.0K $406.1K
Receivables $5.867M $5.513M $4.861M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.76M $30.48M $10.98M
YoY Change 15.88% 177.66% 8.2%
LONG-TERM ASSETS
Property, Plant & Equipment $1.493M $1.540M $888.9K
YoY Change 69.25% 73.28% -10.52%
Goodwill $1.941M $2.008M $0.00
YoY Change -100.0%
Intangibles $1.341M $1.368M $235.1K
YoY Change 492.42% 482.07% -11.9%
Long-Term Investments $308.0K $308.0K
YoY Change
Other Assets $26.14M $10.63M $9.451M
YoY Change 153.99% 12.49% 47.59%
Total Long-Term Assets $28.13M $12.17M $10.34M
YoY Change 151.73% 17.71% 39.78%
TOTAL ASSETS
Total Short-Term Assets $14.76M $30.48M $10.98M
Total Long-Term Assets $28.13M $12.17M $10.34M
Total Assets $42.89M $42.65M $21.32M
YoY Change 79.36% 100.08% 21.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.262M $1.120M $1.363M
YoY Change -34.58% -17.86% -15.09%
Accrued Expenses $2.703M $2.483M $1.826M
YoY Change 4.66% 35.95% 6.23%
Deferred Revenue $8.365M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $2.000M
YoY Change 55.0% 55.0% 0.0%
Total Short-Term Liabilities $15.43M $14.91M $12.60M
YoY Change 10.69% 18.39% 1.49%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $1.425M $1.425M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $35.87M $37.59M $22.12M
YoY Change 59.61% 69.89% -0.1%
Total Long-Term Liabilities $37.29M $39.01M $23.55M
YoY Change 56.05% 65.66% -0.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.43M $14.91M $12.60M
Total Long-Term Liabilities $37.29M $39.01M $23.55M
Total Liabilities $51.30M $52.50M $34.72M
YoY Change 40.88% 51.2% 0.47%
SHAREHOLDERS EQUITY
Retained Earnings -$25.33M -$26.22M -$25.15M
YoY Change 3.49% 4.24% -8.86%
Common Stock $35.65M $35.50M $31.23M
YoY Change 13.17% 13.68% 5.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.57M $19.57M $19.57M
YoY Change 0.0% 0.0% 3.08%
Treasury Stock Shares $5.801M 5.801M shares 5.801M shares
Shareholders Equity -$8.908M -$9.849M -$13.40M
YoY Change
Total Liabilities & Shareholders Equity $42.39M $42.65M $21.32M
YoY Change 77.29% 100.08% 21.52%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income $890.8K $245.0K $652.0K
YoY Change 30.99% -62.43% -124.66%
Depreciation, Depletion And Amortization $103.1K $94.28K $60.00K
YoY Change 71.75% 57.13% -14.29%
Cash From Operating Activities $844.0K $2.769M $1.230M
YoY Change -60.0% 125.15% 13.89%
INVESTING ACTIVITIES
Capital Expenditures -$37.86K -$158.3K -$60.00K
YoY Change -5.35% 163.83% 500.0%
Acquisitions
YoY Change
Other Investing Activities -$31.06K -$10.60M -$10.00K
YoY Change -203.53% 105851.9% -150.0%
Cash From Investing Activities -$68.93K -$10.74M -$60.00K
YoY Change 244.65% 17805.8% -700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.775M 8.485M -1.200M
YoY Change 269.79% -807.08% -66.48%
NET CHANGE
Cash From Operating Activities 844.0K 2.769M 1.230M
Cash From Investing Activities -68.93K -10.74M -60.00K
Cash From Financing Activities -1.775M 8.485M -1.200M
Net Change In Cash -999.9K 510.8K -30.00K
YoY Change -162.11% -1802.73% -98.8%
FREE CASH FLOW
Cash From Operating Activities $844.0K $2.769M $1.230M
Capital Expenditures -$37.86K -$158.3K -$60.00K
Free Cash Flow $881.8K $2.928M $1.290M
YoY Change -58.98% 126.95% 18.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000 shares
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000 shares
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7800833 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4667083
CY2017Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2482920
CY2018Q3 us-gaap Assets Current
AssetsCurrent
30478898
CY2018Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2214373
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5512863
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35360801
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1119703
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
446120
CY2018Q3 us-gaap Assets
Assets
42650360
CY2018Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4698255
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7039972
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7800833 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13596409 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
135965
CY2018Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1605000
CY2018Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
6918125
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8209890
CY2018Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2018Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
19873999
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1368231
CY2018Q3 us-gaap Goodwill
Goodwill
2007976
CY2018Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1368231
CY2018Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
168052
CY2018Q3 us-gaap Inventory Net
InventoryNet
16170057
CY2018Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2018Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
132506
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14912513
CY2018Q3 us-gaap Liabilities
Liabilities
52498860
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42650360
CY2018Q3 us-gaap Long Term Debt
LongTermDebt
14689093
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
11589093
CY2018Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2018Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
949763
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
209202
CY2018Q3 us-gaap Notes Payable
NotesPayable
14983433
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10631220
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
597041
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
37586347
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1540242
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26220273
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
40254 shares
CY2018Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.58
CY2018Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2018Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
294340
CY2018Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
961111 shares
CY2018Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1001365 shares
CY2018Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.77
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-9848500
CY2018Q3 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q3 ccel Inventory Collection Kits
InventoryCollectionKits
27724
CY2018Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
28888
CY2018Q3 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2018Q3 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2 CompensationPlan
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3499881
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2582475
CY2017Q4 us-gaap Assets Current
AssetsCurrent
12736921
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2098991
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5125591
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31373048
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1928542
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40865
CY2017Q4 us-gaap Assets
Assets
23909997
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7103941 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12899517 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
128995
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2316000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
10035388
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7428829
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15752864
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
226418
CY2017Q4 us-gaap Goodwill
Goodwill
0
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
226418
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
210854
CY2017Q4 us-gaap Inventory Net
InventoryNet
314566
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
97210
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13939846
CY2017Q4 us-gaap Liabilities
Liabilities
36412893
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23909997
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
7295183
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5295183
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
439322
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
206136
CY2017Q4 us-gaap Notes Payable
NotesPayable
7500100
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10290694
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
372152
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22473047
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
882382
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24474691
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.41
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
39168 shares
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
204917
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2017Q4 ccel Inventory Collection Kits
InventoryCollectionKits
14220
CY2017Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
28888
CY2017Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
446554
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
709000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
171689
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
96869
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26000
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.08
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
22858031
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-594359
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.08
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1167202
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1696560
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
89000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5085538
us-gaap Costs And Expenses
CostsAndExpenses
15148707
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
73512
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96925
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2763894
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1128012
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122237
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
104669
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2671172
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
1039000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
805398
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-727969
us-gaap Interest Expense
InterestExpense
937248
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25385
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10560
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
613584 shares
us-gaap Interest Expense Debt
InterestExpenseDebt
349685
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-996715
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
105841
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2545224
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3606585
us-gaap Net Income Loss
NetIncomeLoss
1635882
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
60678
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59467
us-gaap Operating Income Loss
OperatingIncomeLoss
3760609
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-161023
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
446621
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55182
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51396
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2149999
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18909316
us-gaap Share Based Compensation
ShareBasedCompensation
709173
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-2876
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23682
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9942562
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7663366 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7049782 shares
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-60425
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
3388
ccel Process And Storage Royalties
ProcessAndStorageRoyalties
820877
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
96869
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
214275
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
79876
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49000
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.52
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
22794591
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3797189
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.52
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
760818
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1340327
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
80000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5864826
us-gaap Costs And Expenses
CostsAndExpenses
17567808
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3117263
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
124865
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Entity Small Business
EntitySmallBusiness
true
dei Document Period End Date
DocumentPeriodEndDate
2018-08-31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-153756
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2076078
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3821660
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-808839
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3066
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3496790
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
3741000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#xA0;5, 2017, the Company increased the $75,000 payment warranty to a $100,000 payment warranty to all of its new clients that enroll in the Company&#x2019;s premium product, PrepaCyte CB. Clients that enroll in the standard product will receive a $75,000 payment warranty. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $100,000, $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of August&#xA0;31, 2018 and November&#xA0;30, 2017 the Company recorded reserves under these programs in the amounts of approximately $18,000 and $18,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets</p> </div>
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
805183
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-99555
us-gaap Interest Expense
InterestExpense
995437
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
473130
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-182466
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
156022
us-gaap Interest Expense Debt
InterestExpenseDebt
393254
ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
20103661
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-980917
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11213483
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7484959
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4489342
us-gaap Net Income Loss
NetIncomeLoss
-1745582
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
405255
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14520
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1405406
us-gaap Operating Income Loss
OperatingIncomeLoss
3056995
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
169300
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
105186
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
408297
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
170925
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1516666
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
539365
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64927
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20624803
us-gaap Share Based Compensation
ShareBasedCompensation
323798
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y2M19D
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11513190
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
51636 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
50550 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
2.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51636 shares
dei Trading Symbol
TradingSymbol
CCEL
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7350868 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7350868 shares
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
12328
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
ccel Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
2985000
ccel Allocated Share Based Compensation Expenses Reversed
AllocatedShareBasedCompensationExpensesReversed
444000
ccel Process And Storage Royalties
ProcessAndStorageRoyalties
742445
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
79876
ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000 shares
ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1142577
ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2017 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238000
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9000
CY2017Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.01
CY2017Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
8212179
CY2017Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-83925
CY2017Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.01
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
686057
CY2017Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
53000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1977475
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
5443708
CY2017Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33359
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
490558
CY2017Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
437000
CY2017Q3 us-gaap Interest Expense
InterestExpense
314890
CY2017Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
134162
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
694623 shares
CY2017Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
103735
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-309656
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
652019
CY2017Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
34038
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5234
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1452233
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
226
CY2017Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6895941
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3432648
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
CY2017Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.03
CY2018Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
7871222
CY2018Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
244984
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7794855 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7100232 shares
CY2017Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
4784
CY2017Q3 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
492208
CY2017Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
30427
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55000
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.03
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
530239
CY2018Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
58000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2486180
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
6951100
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
52072
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
548056
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
303072
CY2018Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
245000
CY2018Q3 us-gaap Interest Expense
InterestExpense
410366
CY2018Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
232946
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
681013 shares
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
204609
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372066
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
244984
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
285255
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38300
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
920122
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22234
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871222
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4390614
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8375675 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7694662 shares
CY2018Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
37536
CY2018Q3 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
539286
CY2018Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28337

Files In Submission

Name View Source Status
0001193125-18-299303-index-headers.html Edgar Link pending
0001193125-18-299303-index.html Edgar Link pending
0001193125-18-299303.txt Edgar Link pending
0001193125-18-299303-xbrl.zip Edgar Link pending
ccel-20180831.xml Edgar Link completed
ccel-20180831.xsd Edgar Link pending
ccel-20180831_cal.xml Edgar Link unprocessable
ccel-20180831_def.xml Edgar Link unprocessable
ccel-20180831_lab.xml Edgar Link unprocessable
ccel-20180831_pre.xml Edgar Link unprocessable
d613943d10q.htm Edgar Link pending
d613943dex311.htm Edgar Link pending
d613943dex312.htm Edgar Link pending
d613943dex313.htm Edgar Link pending
d613943dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending